A material that is unlike most we’ve generally had exposure to, CoCr is in great demand in the orthopedics and aerospace industries, along with titanium. Currently the ‘prime material’ used in these industries for 3D printing, CoCr allows Arcam’s EBM technology to be used to its fullest potential. CoCr provides parts that are unique in the following:
- High resolution
- Production level productivity
- Impeccable material properties
- Arcam xQam – this is an X-ray based detection system, new and completely innovative, created for automatic calibration and improved beam control.
- EBM Control 5.0 – Arcam has created an all new software platform that not only adds functionality, greater efficiency, and accurate beam control, but also new melt strategies, improving build speed and precision.
- MultiBeam – Arcam’s proprietary technology for parallel melting.
As formnext proceeds on, Arcam will be both demonstrating additive manufacturing via Arcam EBM, and corresponding metal powders through AP&C.
“It is exciting to be at Formnext with our teams from the EBM business and the AP&C powder business exhibiting in concert. Arcam is determined to serve the industry through cost efficient solutions thus converting traditional manufacturing into Additive Manufacturing,” says Magnus René, CEO of Arcam.
- Manufacturing redundancy
- Short term capacity increase
- Long term expansion capability
With their AP&C plasma technology, the company is able to take raw materials and then convert them to valuable metal powders that offer a wide range of properties to include flowability, density, chemistry and traceability. It is currently estimated that the company will be offering a powder manufacturing capacity of 750 tons per year, or even more.
Are you at formnext this week? If so, be sure to check out what Arcam has to demonstrate in Hall 3/F20, and also see the AP&C products on display in Hall 3/G08. Discuss in the Arcam forum at 3DPB.com.
Arcam offers EBM systems through Arcam AB in Sweden, powder metals through AP&C in Canada and implant contract manufacturing through DiSanto in the U.S. The company is listed on Nasdaq Stockholm and the Head Office is located in Mölndal, Sweden.